Notable insider buying and selling activity across public companies.
Tracking and analysis of reported insider transactions, including executive and director buying or selling. Insider activity can offer insight into internal confidence, valuation perceptions, and potential inflection points.
10,141 total articles
Chad Patterson, Chief Communications & Product Officer at iRhythm Holdings, sold 8,967 shares on February 25, 2026, for roughly $1.2 million, according to a Form 4 filing. After the sale Patterson directly held 51,738 shares. The day before the sale he was credited with 17,318 shares at a value of $0 after the board committee determined performance…
Catherine E. Dunn, Vice President and Chief Accounting Officer of Oceaneering International Inc (OII), sold a total of 9,645 shares across transactions on February 24-25, 2026, realizing proceeds of $362,982. Insider sales occurred while the stock traded close to its 52-week peak and after the company reported fourth-quarter 2025 earnings that beat…
iRhythm Holdings Inc. Chief Financial Officer Daniel G. Wilson sold 5,188 shares on February 25, 2026, for $135.42 each, generating $702,553 in proceeds. The day prior he received 9,412 shares at no cost after the company’s compensation committee determined performance conditions tied to 2023 restricted stock units had been met. The transactions le…
Kristen Ambrose, Senior Vice President and Chief Accounting Officer at Vertex Pharmaceuticals (VRTX), reported a sale of 223 shares on February 25, 2026, under a company-approved 10b5-1 plan. The transaction, along with an earlier disposal on February 24, 2026, leaves Ambrose with 6,981 shares. The company’s shares trade near $480 while recent quar…
Xometry Inc. Chief Technology Officer Raghavan Vaidyanathan sold 4,572 Class A shares on February 26, 2026, for about $198,625 to satisfy tax withholding tied to vested restricted stock units. The trades were automatic under a Rule 10b5-1 plan. The transactions follow a February 24, 2026 vesting of 30,479 RSUs at $0.00 and leave Vaidyanathan with 6…
Uma M. Amuluru, Boeing's Executive Vice President and Chief Human Resources Officer, sold 1,503.45 shares of company stock on February 24, 2026, generating about $351,484. The transaction was reported on a Form 4 filing with the Securities and Exchange Commission. The sale occurred as Boeing stock has risen 32% over the past year, though InvestingP…
Donald E. Bobo Jr., Corporate Vice President for Strategy and Corporate Development at Edwards Lifesciences Corp (NYSE: EW), sold 24,000 shares on February 25, 2026, bringing in $2,012,076 at a weighted average price of $83.8365. The sale occurred while the stock trades close to its 52-week peak and follows the company’s mixed fourth-quarter 2025 f…
Xometry Chief Executive Randolph Altschuler sold 25,628 Class A shares on February 26, 2026, in automated transactions tied to a pre-established Rule 10b5-1 plan to meet tax-withholding obligations from vested restricted stock units. The company also reported Q4 2025 results that beat consensus on both earnings and revenue.
David C. Abrams, a director and ten percent owner of ContextLogic Holdings Inc (NASDAQ: LOGC), filed a Form 4 disclosing a purchase of 1,758,794 shares on February 26, 2026. The shares were acquired at $7.00 each for a total of $12,311,558. After the transaction, Abrams directly and indirectly holds 18,269,534 shares. The purchase was reported seve…
BioMarin Pharmaceutical Inc. EVP and Chief R&D Officer Gregory R. Friberg sold 6,326 shares on February 26, 2026 for a weighted average price of $60.3758, totaling $381,937. The transaction left him with 37,578 shares. Separately, BioMarin reported fourth-quarter 2025 results that missed EPS estimates but topped revenue expectations, prompting a ra…
On February 26, 2026, director Bobbili Raja purchased 1,758,794 shares of ContextLogic Holdings Inc. (NASDAQ: LOGC) at $7.00 per share, a transaction valued at $12,311,558. Following the purchase, Raja's indirect holdings across several investment vehicles total 18,269,534 shares. The stock is trading at $7.98 with a market capitalization of $215 m…
A group of Abrams Capital-affiliated funds acquired 1,758,794 shares of ContextLogic Holdings Inc (LOGC) at $7.00 per share on February 26, 2026, a transaction that totaled $12,311,558. The purchase was reported on an SEC Form 4 and increases the combined Abrams position to 18,269,534 shares. The trade represents roughly 5.7% of ContextLogic's $215…
George Eric Davis, BioMarin Pharmaceutical's Executive Vice President and Chief Legal Officer, sold 26,061 shares of company stock on February 26, 2026, for about $1.6 million. The transaction occurred near the stock's trading level, while the company reported fourth-quarter 2025 results that beat revenue expectations but missed on EPS. Multiple an…
PennyMac Financial Services Chief Legal Officer Derek Stark sold 1,903 shares under a Rule 10b5-1 plan on February 25, 2026, generating about $174,124. The transactions follow tax-withholding of 345 shares tied to vested restricted stock units and come amid a sharp year-to-date share decline and a notable Q4 2025 earnings miss for the firm.
Barry J. Simon, a director at ImmunityBio, sold 75,000 shares of the company on February 24, 2026, under a pre-arranged Rule 10b5-1 plan. The transaction totaled $900,787 at a weighted average price of $12.0105. Separately, ImmunityBio reported ANKTIVA revenue of $113 million for 2025 and expanded commercial partnerships in Europe and the Middle Ea…
Eagle Point Credit Management LLC and Eagle Point DIF GP I LLC, each 10% owners of ACRES Commercial Realty Corp, sold a combined 3,701 shares of the company's 8.625% Series C Preferred Stock between February 24 and February 26, 2026, for a total of $93,489. After the transactions the entities continue to hold substantial positions in both preferred…
Director Marx Felix sold 3,000 shares of Socket Mobile, Inc. (NASDAQ: SCKT) on February 24, 2026, in a transaction that generated $3,000 in proceeds. The sale was disclosed in a Form 4 filing with the SEC. Following the sale, Felix held 8,643 shares. The stock is trading at $0.90, down 11% over the prior week and 20% over the past year, with a mark…
Bloom Energy Chairman and CEO Sridhar KR sold 200,000 Class A shares on February 24, 2026, for about $34 million, at prices between $170.00 and $170.05 per share. The transaction leaves him with 2,189,869 Class A shares. The sale coincides with a stock trading at $168.57 after a 632% gain over the past year and follows a strong Q4 2025 in which Blo…
Director Paul B. Manning bought 550,458 shares of Candel Therapeutics (NASDAQ: CADL) on February 23, 2026, paying $5.45 per share for a total of $2,999,996. The transaction occurred while the stock was trading at $5.15. Manning's direct and indirect holdings, plus recent company filings, outline both insider accumulation and a $100 million public o…
ReposiTrak Chief Executive Officer Randall K. Fields sold 7,500 shares of common stock across February 24 and 25, 2026, through a pre-arranged Rule 10b5-1 plan, generating $62,891 in proceeds. The transactions were reported on a Form 4 filing with the SEC. The company has also declared a quarterly dividend, authorized a new 10b5-1 buyback allocatio…
SkyWest Inc. Chief Commercial Officer Wade J. Steel disposed of 20,629 shares on February 24, 2026, receiving roughly $2.2 million. The transaction occurred at a weighted average price of $106.5281. The company recently reported fourth-quarter 2025 results that topped analyst forecasts, while InvestingPro analysis notes the stock is overvalued vers…
Director Jack Bendheim and BFI Co., LLC, a ten percent owner of Phibro Animal Health Corp (NASDAQ: PAHC), sold a combined $1.1 million in Class A common stock between February 24 and February 26, 2026. The disposition comprised 20,120 shares executed under a Rule 10b5-1 trading plan adopted May 30, 2025. The stock is trading near its 52-week high, …
BlackRock Senior Managing Director J. Richard Kushel sold 2,385 shares of BlackRock stock on February 24, 2026, in two transactions that generated $2.58 million in proceeds. The trades were executed at prices between $1,083.05 and $1,084.9101 per share. After the sales, Kushel retains both direct and indirect holdings in the company. The transactio…
Ourania Tatsis, Executive Vice President at Vertex Pharmaceuticals, sold shares under a pre-established Rule 10b5-1 trading plan, disposing of 1,887 shares across two days for roughly $915,724. The trades were filed on a Form 4 with the SEC. Vertex shares trade near their 52-week high even as the company reported a slight EPS miss for Q4 2025 and a…
Amit Sachdev, Vertex Pharmaceuticals' Executive Vice President and Chief Patient & External Affairs Officer, executed two share dispositions across February 24-25, 2026, via a company-approved 10b5-1 trading plan. The transactions reduced his directly held stake while leaving him with substantial direct and indirect holdings. The stock sales oc…
